MindBio Therapeutics Expands AI Intoxication Detection with New Data Collection Platform
MindBio Therapeutics has launched Intox Collect™, broadening its AI-driven intoxication detection capabilities beyond alcohol to include multiple central nervous system stimulants and depressants, with implications for workplace safety across high-risk industries.
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) has expanded its artificial intelligence-based intoxication detection platform with the launch of Intox Collect™, a software tool designed to enhance the company's ability to collect and analyze voice and facial recognition data related to drug and alcohol impairment. The technology broadens detection capabilities beyond alcohol to include multiple central nervous system stimulants and depressants, representing a significant advancement in workplace safety technology.
The company's AI model currently utilizes more than 50 million data points, with management expecting that figure to increase further as the platform expands. This extensive dataset forms the foundation for MindBio's detection algorithms, which analyze subtle changes in voice patterns and facial expressions that may indicate impairment from various substances affecting the central nervous system.
MindBio is developing Edge AI kiosk hardware for enterprise deployment, with prototype testing expected in the second quarter of 2026. The hardware solution aims to provide organizations with on-site intoxication detection capabilities that can be integrated into existing safety protocols and compliance frameworks.
Target industries for the technology include mining, aviation, construction, law enforcement, and any environments where intoxication testing is frequently required for safety and compliance purposes. These sectors often face significant challenges in maintaining workplace safety standards while ensuring efficient operations, making advanced detection technologies particularly valuable.
The expansion of MindBio's platform comes at a time when workplace safety regulations are becoming increasingly stringent across multiple industries. The ability to detect impairment from a wider range of substances could help organizations better comply with safety standards while potentially reducing accidents and improving overall workplace safety outcomes.
For investors seeking additional information, the latest news and updates relating to MBQIF are available in the company's newsroom at https://ibn.fm/MBQIF. The development of Intox Collect™ represents a strategic expansion of MindBio's technology portfolio and positions the company to address growing demand for comprehensive intoxication detection solutions across multiple high-risk industries.